Clinical and Serological Analysis of Patients with Positive Anticyclic Citrullinated Peptide Antibodies Referred Through a Rheumatology Central Triage System

REFERENCES

1. 1.↵
   1. Schellekens GA,
   2. de Jong BA,
   3. van den Hoogen FH,
   4. van de Putte LB,
   5. van Venrooij WJ

   . Citrulline is an essential constituent on antibodies recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273–81.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Schellekens GA,
   2. Visser H,
   3. de Jong BA,
   4. van den Hoogen FH,
   5. Hazes JM,
   6. Breedveld FC,
   7. et al.

   The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155–63.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Aletaha D,
   2. Neogi T,
   3. Silman AJ,
   4. Funovits J,
   5. Felson DT,
   6. Bingham CO 3rd,
   7. et al.

   2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Neogi T,
   2. Aletaha D,
   3. Silman AJ,
   4. Naden RL,
   5. Felson DT,
   6. Aggarwal R,
   7. et al.

   The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010;62:2582–91.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. van Venrooij WJ,
   2. van Beers JJ,
   3. Pruijn GJ

   . Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011;7:391–8.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Willemze A,
   2. Trouw LA,
   3. Toes RE,
   4. Huizinga TW

   . The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012;8:144–52.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Rantapää-Dahlqvist S,
   2. de Jong BA,
   3. Berglin E,
   4. Hallmans G,
   5. Wadell G,
   6. Stenlund H,
   7. et al.

   Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741–9.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Rakieh C,
   2. Nam JL,
   3. Hunt L,
   4. Hensor EM,
   5. Das S,
   6. Bissell LA,
   7. et al.

   Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis 2014 Apr 12 (E-pub ahead of print).
9. 9.↵
   1. Maehlen MT,
   2. Olsen IC,
   3. Andreassen BK,
   4. Viken MK,
   5. Jiang X,
   6. Alfredsson L,
   7. et al.

   Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis. Ann Rheum Dis 2013 Dec 13 (E-pub ahead of print).
10. 10.↵
    1. Fitch-Rogalsky C,
    2. Steber W,
    3. Mahler M,
    4. Lupton T,
    5. Martin L,
    6. Barr SG,
    7. et al.

    Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 2014;9:e93812.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. nan Venrooij WJ,
    2. Zendman AJ

    . Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clin Rev Allergy Immunol 2008;34:36–9.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Rantapää-Dahlqvist S

    . What happens before the onset of rheumatoid arthritis? Curr Opin Rheumatol 2009;21:272–8.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Bossuyt X,
    2. Coenen D,
    3. Fieuws S,
    4. Verschueren P,
    5. Westhovens R,
    6. Blanckaert N

    . Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 2009;68:287–9.

    OpenUrlFREE Full Text
14. 14.↵
    1. Swart A,
    2. Burlingame RW,
    3. Gürtler I,
    4. Mahler M

    . Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta 2012;414:266–72.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Bossuyt X,
    2. Frans J,
    3. Hendrickx A,
    4. Luyckx A,
    5. De Vlam K,
    6. Verschueren P,
    7. et al.

    Detection of anti-nucleosome antibodies in a routine clinical laboratory setting. Clin Exp Rheumatol 2008;26:387–8.

    OpenUrlPubMed
16. 16.↵
    1. Shoenfeld Y,
    2. Cervera R,
    3. Haass M,
    4. Kallenberg C,
    5. Khamashta M,
    6. Meroni P,
    7. et al.

    EASI - The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann N Y Acad Sci 2007;1109:138–44.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Man A,
    2. Shojania K,
    3. Phoon C,
    4. Pal J,
    5. de Badyn MH,
    6. Pi D,
    7. et al.

    An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing. Clin Rheumatol 2013;32:601–8.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Bonaguri C,
    2. Melegari A,
    3. Ballabio A,
    4. Parmeggiani M,
    5. Russo A,
    6. Battistelli L,
    7. et al.

    Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun Rev 2011;11:1–5.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Watanabe A,
    2. Kodera M,
    3. Sugiura K,
    4. Usuda T,
    5. Tan EA,
    6. Takasaki Y,
    7. et al.

    Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892–900.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Trouw LA,
    2. Mahler M

    . Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012;12:318–22.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Plenge RM,
    2. Bridges SL Jr

    . Personalized medicine in rheumatoid arthritis: miles to go before we sleep. Arthritis Rheum 2011;63:590–3.

    OpenUrlCrossRefPubMed